In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations

被引：0
|
作者：
Fischer, J. [1 ]
Bouhana, K. [1 ]
Chicarelli, M. J. [1 ]
Dahlke, J. [1 ]
Fell, B. [1 ]
Fulton, J. [1 ]
Guarnieri, A. [1 ]
Haygood, L. [1 ]
Jalluri, R. [1 ]
Johnson, A. [1 ]
McLean, B. [1 ]
Max, M. [1 ]
Rieger, R. [1 ]
Robinson, J. [1 ]
Rodriguez, M. [1 ]
Sullivan, F. [1 ]
Wang, Y. [1 ]
Winski, S. [1 ]
Zhou, Y. [1 ]
机构：
[1] Cogent Biosci, Res Dev, Boulder, CO USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
227
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 46 条
  • [1] Pre-clinical characterization of a novel series of FGFR2 selective inhibitors with potency against clinically relevant mutations
    Fischer, John
    Bouhana, Karyn
    Chicarelli, Mark J.
    Dahlke, Josh
    Fell, Brad
    Fulton, Jennifer
    Guarnieri, Anna
    Jalluri, Ravi
    Johnson, Amber
    Mclean, Brent
    Mejia, Max
    Rieger, Rob
    Robinson, John
    Rodriguez, Mareli
    Sullivan, Francis
    Wang, Yang
    Winski, Shannon
    Zhou, Yeyun
    CANCER RESEARCH, 2022, 82 (12)
  • [2] In vivo characterization of a selective FGFR2 inhibitor with potency against gatekeeper and molecular brake mutations
    Fischer, John
    Bouhana, Karyn
    Chicarelli, Mark
    Fell, Brad
    Fulton, Jennifer
    Guarnieri, Anna
    Haygood, Leyla
    Jalluri, Ravi
    Johnson, Amber
    Mclean, Brent
    Mejia, Max
    Rieger, Rob
    Robinson, John
    Rodriguez, Mareli
    Sullivan, Francis
    Wang, Yang
    Winski, Shannon
    Zhou, YeYun
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Identification of a reversible selective FGFR2 clinical development candidate with potency against gatekeeper and molecular brake mutations
    Fischer, John
    Bouhana, Karyn
    Brizendine, Richard
    Chicarelli, Mark
    Fell, Brad
    Fulton, Jennifer
    Guarnieri, Anna
    Haygood, Leyla
    Jalluri, Ravi
    Johnson, Amber
    Koch, Keith
    Koslov-Davino, Erika
    Mejia, Max
    Rieger, Rob
    Robinson, John
    Rodriguez, Mareli
    Sullivan, Francis
    Wang, Yang
    Winski, Shannon
    Wood, Silas
    Zhou, Yeyun
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [4] Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers
    Dardenne, Etienne
    Padilla, Fernando
    Rasmussen, Sara
    Yang, Shao Ning
    Mentes, Ahmet
    Ogawa, Luisa Shin
    Trombino, Anthony
    Romashko, Darlene
    Chevtsova, Maria
    Thakur, Shalabh
    Buck, Elisabeth
    Roberts, Christopher
    Lucas, Matthew
    Lin, Tai-An
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [5] Discovery and characterization of selective, FGFR1-sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers
    Dardenne, E.
    Padilla, F.
    Rasmussen, S.
    Yang, S. N.
    Mentes, A.
    Ogawa, L. S.
    Fiorenza, R.
    Trombino, A.
    Smith, S.
    Romashko, D.
    Ishiyama, N.
    Chevtsova, M.
    Thakur, S.
    Rosfjord, E.
    Buck, E.
    Roberts, C.
    Lucas, M.
    Lin, T-A.
    ANNALS OF ONCOLOGY, 2021, 32 : S15 - S15
  • [6] Pre-clinical In Vitro and In Vivo Characterization of a Novel EGFR Sparing ErbB2 Inhibitor with Activity Against Oncogenic ErbB2 Mutations
    Chicarelli, M. J.
    Bouhana, K.
    Cable, L.
    Crow, M.
    Fell, B.
    Fischer, J.
    Fulton, J.
    Guarnieri, A.
    Jalluri, R.
    Robinson, J.
    Sullivan, F.
    Winski, S.
    Zhou, Y.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S81 - S81
  • [7] Characterization of two novel oncogenic FGFR2 fusions sensitive to the FGFR-selective inhibitor Debio 1347 in cholangiocarcinoma
    Vaslin, Anne
    Rigotti, Stefania
    Lembrez, Nathalie
    Vuagniaux, Gregoire
    Moulon, Corinne
    Tanaka, Hiroaki
    CANCER RESEARCH, 2015, 75
  • [8] Pre-clinical characterization of potent and selective next-generation RET inhibitors.
    Kolakowski, Gabrielle R.
    Anderson, Erin D.
    Ballard, Joshua A.
    Brandhuber, Barbara J.
    Condroski, Kevin R.
    Gomez, Eliana B.
    Irvin, Thomas C.
    Kumar, Manoj
    Patel, Nisha A.
    Watson, Faith D.
    Andrews, Steven W.
    CANCER RESEARCH, 2021, 81 (13)
  • [9] Discovery of highly selective DUB inhibitors with in vivo pre-clinical anti-tumor activity
    Jacq, Xavier
    Martin, Niall M. B.
    Smith, Lisa
    Harrigan, Jeanine
    Knights, Charlotte
    Robinson, Helen
    Ofir-Rosenfeld, Yaara
    Cranston, Aaron
    Kemp, Mark I.
    Jackson, Stephen P.
    CANCER RESEARCH, 2015, 75
  • [10] Genomic and clinical characterization of non-small cell lung cancer (NSCLC) patients harboring mutations in FGFR2 and FGFR3
    Scheffler, M.
    Chanra, T.
    Kron, A.
    Koleczko, S.
    Abdulla, D. S. Y.
    Ihle, M. A.
    Holzem, A.
    Riedel, R.
    Michels, S.
    Fischer, R. N.
    Merkelbach-Bruse, S.
    Buettner, R.
    Nogova, L.
    Wolf, J.
    ANNALS OF ONCOLOGY, 2019, 30
12345